News
Sarepta reports second patient death after treatment with Duchenne gene therapy
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who received the treatment.
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over ...
Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...
The death of a second patient taking Sarepta Therapeutics' controversial gene therapy for Duchenne muscular dystrophy caused shares of Sarepta to plunge, and raised questions about the viability of ...
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback